Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ablation procedure and/or cardioversion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ablation Management |
| Name | Type | Description |
|---|---|---|
| Ablation procedure and/or cardioversion | PROCEDURE | Ablation Frontiers Cardiac Ablation System |
Inclusion Criteria: * History of symptomatic permanent atrial fibrillation * Age between 18 and 70 * Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study Exclusion Criteria: * Structural heart disease of clinical significance * ...
The ablation procedure and/or cardioversion is used for atrial fibrillation, a heart rhythm disorder. It is a cardiovascular treatment developed by Medtronic plc. The procedure is intended to address abnormal heart rhythms in patients with this condition.
Medtronic plc (NYSE: MDT) develops the ablation procedure and/or cardioversion. This cardiovascular treatment is part of Medtronic's portfolio for managing atrial fibrillation. The company is a major medical device manufacturer.
The ablation procedure and/or cardioversion is in Phase 1 clinical development. It is an investigational treatment for atrial fibrillation. The Phase 1 trial has been completed, and the treatment is not yet approved for commercial use.
The ablation procedure and/or cardioversion has one completed clinical trial, NCT00744835, titled "Atrial Fibrillation Ablation Pilot Study." This Phase 1 study enrolled 53 participants with atrial fibrillation and was conducted in the Netherlands, Switzerland, and the United Kingdom.
The ablation procedure and/or cardioversion is not FDA approved. It is an investigational treatment currently in Phase 1 clinical development. The completed pilot study provides preliminary data, but the treatment has not yet received regulatory approval.